Cargando…
Clinical spectrum and pleiotropic nature of CDH1 germline mutations
CDH1 encodes E-cadherin, a key protein in adherens junctions. Given that E-cadherin is involved in major cellular processes such as embryogenesis and maintenance of tissue architecture, it is no surprise that deleterious effects arise from its loss of function. E-cadherin is recognised as a tumour s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581119/ https://www.ncbi.nlm.nih.gov/pubmed/30661051 http://dx.doi.org/10.1136/jmedgenet-2018-105807 |
_version_ | 1783428138758307840 |
---|---|
author | Figueiredo, Joana Melo, Soraia Carneiro, Patrícia Moreira, Ana Margarida Fernandes, Maria Sofia Ribeiro, Ana Sofia Guilford, Parry Paredes, Joana Seruca, Raquel |
author_facet | Figueiredo, Joana Melo, Soraia Carneiro, Patrícia Moreira, Ana Margarida Fernandes, Maria Sofia Ribeiro, Ana Sofia Guilford, Parry Paredes, Joana Seruca, Raquel |
author_sort | Figueiredo, Joana |
collection | PubMed |
description | CDH1 encodes E-cadherin, a key protein in adherens junctions. Given that E-cadherin is involved in major cellular processes such as embryogenesis and maintenance of tissue architecture, it is no surprise that deleterious effects arise from its loss of function. E-cadherin is recognised as a tumour suppressor gene, and it is well established that CDH1 genetic alterations cause diffuse gastric cancer and lobular breast cancer—the foremost manifestations of the hereditary diffuse gastric cancer syndrome. However, in the last decade, evidence has emerged demonstrating that CDH1 mutations can be associated with lobular breast cancer and/or several congenital abnormalities, without any personal or family history of diffuse gastric cancer. To date, no genotype–phenotype correlations have been observed. Remarkably, there are reports of mutations affecting the same nucleotide but inducing distinct clinical outcomes. In this review, we bring together a comprehensive analysis of CDH1-associated disorders and germline alterations found in each trait, providing important insights into the biological mechanisms underlying E-cadherin’s pleiotropic effects. Ultimately, this knowledge will impact genetic counselling and will be relevant to the assessment of risk of cancer development or congenital malformations in CDH1 mutation carriers. |
format | Online Article Text |
id | pubmed-6581119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-65811192019-07-05 Clinical spectrum and pleiotropic nature of CDH1 germline mutations Figueiredo, Joana Melo, Soraia Carneiro, Patrícia Moreira, Ana Margarida Fernandes, Maria Sofia Ribeiro, Ana Sofia Guilford, Parry Paredes, Joana Seruca, Raquel J Med Genet Cancer Genetics CDH1 encodes E-cadherin, a key protein in adherens junctions. Given that E-cadherin is involved in major cellular processes such as embryogenesis and maintenance of tissue architecture, it is no surprise that deleterious effects arise from its loss of function. E-cadherin is recognised as a tumour suppressor gene, and it is well established that CDH1 genetic alterations cause diffuse gastric cancer and lobular breast cancer—the foremost manifestations of the hereditary diffuse gastric cancer syndrome. However, in the last decade, evidence has emerged demonstrating that CDH1 mutations can be associated with lobular breast cancer and/or several congenital abnormalities, without any personal or family history of diffuse gastric cancer. To date, no genotype–phenotype correlations have been observed. Remarkably, there are reports of mutations affecting the same nucleotide but inducing distinct clinical outcomes. In this review, we bring together a comprehensive analysis of CDH1-associated disorders and germline alterations found in each trait, providing important insights into the biological mechanisms underlying E-cadherin’s pleiotropic effects. Ultimately, this knowledge will impact genetic counselling and will be relevant to the assessment of risk of cancer development or congenital malformations in CDH1 mutation carriers. BMJ Publishing Group 2019-04 2019-01-19 /pmc/articles/PMC6581119/ /pubmed/30661051 http://dx.doi.org/10.1136/jmedgenet-2018-105807 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Cancer Genetics Figueiredo, Joana Melo, Soraia Carneiro, Patrícia Moreira, Ana Margarida Fernandes, Maria Sofia Ribeiro, Ana Sofia Guilford, Parry Paredes, Joana Seruca, Raquel Clinical spectrum and pleiotropic nature of CDH1 germline mutations |
title | Clinical spectrum and pleiotropic nature of CDH1 germline mutations |
title_full | Clinical spectrum and pleiotropic nature of CDH1 germline mutations |
title_fullStr | Clinical spectrum and pleiotropic nature of CDH1 germline mutations |
title_full_unstemmed | Clinical spectrum and pleiotropic nature of CDH1 germline mutations |
title_short | Clinical spectrum and pleiotropic nature of CDH1 germline mutations |
title_sort | clinical spectrum and pleiotropic nature of cdh1 germline mutations |
topic | Cancer Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581119/ https://www.ncbi.nlm.nih.gov/pubmed/30661051 http://dx.doi.org/10.1136/jmedgenet-2018-105807 |
work_keys_str_mv | AT figueiredojoana clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT melosoraia clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT carneiropatricia clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT moreiraanamargarida clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT fernandesmariasofia clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT ribeiroanasofia clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT guilfordparry clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT paredesjoana clinicalspectrumandpleiotropicnatureofcdh1germlinemutations AT serucaraquel clinicalspectrumandpleiotropicnatureofcdh1germlinemutations |